RecruitingNot Applicable

Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis

South Africa2,500 participantsStarted 2024-08-01

Plain-language summary

TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Active RR-TB diagnosed at a study facility during the study period
✓. Positive Mtb culture, smear, or specimen derivative (e.g., GenoLyse remnant, Xpert cartridge extract)

Exclusion criteria

✕. Patient expects to relocate/move residence outside of the study region
✕. Patient does not agree to participate in the study

What they're measuring

Number of participants with prespecified end of treatment outcomes

Timeframe: At the anticipated completion of prescribed treatment, up to 18 months

Trial details

NCT IDNCT05553236

SponsorUniversity of California, San Francisco

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-01

Contact for this trial

John Z Metcalfe, MD, PhD

+14152068314 john.metcalfe@ucsf.edu

View on ClinicalTrials.gov More Drug-resistant Tuberculosis trials